Medical technology company supplying closed-system transfer devices (PhaSeal), infusion systems, flow cytometers, and single-cell tools.
BD, Becton, Dickinson and Company, based in Franklin Lakes, New Jersey, and listed as BDX, is a medical technology company supplying closed-system transfer devices such as PhaSeal, infusion systems, flow cytometers and single-cell tools. Its oncology footprint spans hazardous-drug handling, BD Cato compounding software, FACS flow cytometry used for measurable residual disease and the BD Rhapsody single-cell platform. OnCo links it to pharmacy automation, multiparameter flow cytometry MRD, cell-therapy release testing and infusion devices. Whether flow cytometry keeps its place in MRD as sequencing-based tests spread is the open question for one part of its business. The flow cytometry MRD page carries the evidence.
Shares Infusion pumps, ports, and ambulatory chemotherapy devices, Oncology pharmacy automation and compounding robots, Closed-system transfer devices for hazardous drugs (PhaSeal, ChemoLock, Equashield) and the tag supporting.
Shares Oncology pharmacy automation and compounding robots, Closed-system transfer devices for hazardous drugs (PhaSeal, ChemoLock, Equashield) and the tag supporting.
Shares Infusion pumps, ports, and ambulatory chemotherapy devices, Closed-system transfer devices for hazardous drugs (PhaSeal, ChemoLock, Equashield) and the tag supporting.
Shares Infusion pumps, ports, and ambulatory chemotherapy devices and the tag supporting.
Shares Cell-therapy release and potency testing and the tag supporting.
Shares Cell-therapy release and potency testing, Flow cytometers and the tag supporting.
Shares Oncology pharmacy automation and compounding robots and the tag supporting.
Shares Flow cytometers and the tag supporting.